Ampyra (dalfampridine) was approved on January 22, 2010, to improve walking in patients with multiple sclerosis (MS).
To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program using the information at the bottom of this page.
- FDA Drug Safety Communication: Seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine)
- FDA Drug Safety Podcast for Healthcare Professionals: Seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine)
- FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis